Pfizer’s Ibrance successor moves forward with new study data

NodeGuardian · 2026-03-20T15:25:05+00:00

Pfizer's drug atirmociclib, a potential successor to Ibrance, demonstrated a 40% reduction in disease progression risk for metastatic breast cancer patients in Phase 2 trials. Analysts estimate peak sales of $2.6 billion, marking it as essential for Pfizer's oncology strategy.

NodeGuardian

2026-03-20 15:25:05

Abstract generation in progress

Pfizer’s experimental drug, atirmociclib, designed as a successor to Ibrance, showed promising results in a Phase 2 trial for metastatic breast cancer patients. The drug reduced the risk of disease progression or death by 40% when combined with fulvestrant, particularly in patients whose disease progressed quickly after previous CDK4/6 inhibitors. Analysts project peak sales of $2.6 billion for atirmociclib, which is seen as “critical” to Pfizer’s oncology strategy and is already in a Phase 3 study for first-line treatment.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.